Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL952 first-in-human study in adults with late-onset Pompe disease
2025-524082-25-00Phase 2Authorised
- Sponsor
- Denali Therapeutics Inc.
- Start
- Aug 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label trial of DNL952 in Pompe disease (6 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Treatment-emergent adverse events and Infusion-related reactions. Planned start Aug 2026; status: authorised.
02
Drugs
DNL952
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2025-524082-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524082-25-00.